Figure 7.
Response to checkpoint therapy in B16F10 is increased in reconstituted animals, consistent with increases in baseline inflammation. Unirradiated, age matched controls (A and B) and animals that were irradiated with 7 gray of X-Ray irradiation and reconstituted with donor bone marrow (C and D) were implanted with 4 × 105 B16F10 syngeneic melanoma cells subcutaneously. On day 11 post-implantation, animals were randomized into treatment groups that received either isotype antibody (A and C) or anti-CTLA-4 antibody (B and D). Tumor volumes were measured twice a week until the tumors exceeded 800 mm3.